Jeil Pharmaceutical: CEO Seong Seok-je Re-elected for 8th Term & Key Decisions from Shareholder Meeting

Seoul, South Korea – Shareholders of 제일약품 (Jeil Pharmaceutical) and its holding company, 제일파마홀딩스 (Jeil Pharma Holdings), have re-elected Seong Seok-je and Han Sang-cheol as internal directors, according to voting results announced on March 24, 2026. The decisions came during separate general shareholder meetings held at the companies’ headquarters in Seoul’s Seocho district.

Jeil Pharmaceutical reported consolidated revenue of 567.2 billion Korean won, operating profit of 20.7 billion won, and net profit of 32 billion won for the fiscal year 2025. The company attributed the improved profitability to an expansion of sales focused on its own products and improvements in cost of goods sold, as reported to shareholders.

During the meetings, shareholders approved the financial statements, amendments to the company’s articles of association, the appointment of directors, the appointment of external directors, the appointment of external directors as auditors, the separate election of external directors serving as auditors, revisions to the retirement benefit regulations for executives, and the approval of director compensation limits.

In addition to the re-election of Seong and Han, Kim Seong-hoon was newly appointed as an external director and also as an auditor. Kim Wang-seong, an existing external director, was also re-elected as an external director serving as an auditor.

Seong Seok-je, CEO of Jeil Pharmaceutical, stated that the company is shifting away from a product-centric structure towards a business portfolio focused on its own products to establish a foundation for qualitative growth. He highlighted plans to expand prescriptions for the company’s novel drug, ‘Jacubo,’ and strengthen product competitiveness. Jeil Pharmaceutical is also prioritizing the development of its research pipeline, including the Type 2 diabetes treatment ‘JP-2266,’ to build a foundation for long-term growth.

Jeil Pharma Holdings also held its 66th regular general meeting of shareholders, reporting consolidated revenue of 657.6 billion won, operating profit of 38.7 billion won, and net profit of 34.6 billion won for the year. The company cited improvements in profitability and business structure efficiency at its key subsidiary, Jeil Pharmaceutical, as contributing factors to the financial recovery.

Shareholders of Jeil Pharma Holdings also approved all agenda items, including a dividend of 70 won per share.